Entrada Therapeutics (NASDAQ: TRDA) revenue
Entrada Therapeutics reported revenue of $25.4m for fiscal 2025, 87.9% less than in fiscal 2024 ($210.8m). Since fiscal 2023 its revenue has fallen by 80.3%, an average decline of 55.6% a year.
Entrada Therapeutics's best year of the last 3 was fiscal 2024. The biggest drop was in fiscal 2025, −87.9%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $25.4m | −87.9% | −$157.9m | −621.1% |
| 2024 | $210.8m | +63.4% | $47.0m | 22.3% |
| 2023 | $129.0m | — | −$3.2m | −2.5% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Entrada Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Entrada Therapeutics ranks 352nd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Entrada Therapeutics, −87.9%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 350th | Verastem | $30.9m | 209.1% |
| 351st | Foghorn Therapeutics | $30.9m | 36.8% |
| 352nd | Entrada Therapeutics | $25.4m | −87.9% |
| 353rd | Alumis | $24.1m | — |
| 354th | Alector | $21.0m | −79.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Entrada Therapeutics
- How much revenue did Entrada Therapeutics make in fiscal 2025?
- Entrada Therapeutics reported revenue of $25.4m for fiscal 2025, compared with $210.8m in fiscal 2024.
- How much has the revenue of Entrada Therapeutics fallen?
- Between fiscal 2023 and fiscal 2025 it went from $129.0m to $25.4m: 80.3% less, an average decline of 55.6% a year.
- What was the best year for revenue at Entrada Therapeutics?
- Of its last 3 fiscal years, fiscal 2024, with $210.8m.
- Where does Entrada Therapeutics rank in its sector by revenue?
- It ranks 352nd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Entrada Therapeutics come from?
- From the annual report (Form 10-K) that Entrada Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Entrada Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023. More on Entrada Therapeutics: the Entrada Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.